---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000044"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-08-05T20:18:02+00:00"
generated_at: "2026-08-05T20:19:39.666643+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q2 net loss widens to $55.4M; revenue drops to $4.1M; new Jazz, Vertex deals

## Summary
- Net loss of $55.4M ($0.18/sh) vs $34.7M ($0.12/sh) in Q2 2025; revenue $4.1M vs $17.1M.
- Ended quarter with >$565M cash and marketable securities; total liquidity >$675M.
- Announced collaborations with Jazz ($84M upfront) and Vertex ($28M upfront) for T-cell engagers.
- ABCL635 Phase 2 top-line data expected in August 2026; ABCL575 Phase 1 data expected Q4 2026.
- Partner programs progressing: 35 (down from 44 at Dec 2025); 12 molecules in clinic.

## SEC filing metadata
- accession: 0001703057-26-000044
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-08-05T20:18:02+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/0001703057-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/abcl-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000044
- JSON: https://secwatch.observer/filing/0001703057-26-000044.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.